Your browser doesn't support javascript.
loading
The out-of-field dose in radiation therapy induces delayed tumorigenesis by senescence evasion.
Goy, Erwan; Tomezak, Maxime; Facchin, Caterina; Martin, Nathalie; Bouchaert, Emmanuel; Benoit, Jerome; de Schutter, Clementine; Nassour, Joe; Saas, Laure; Drullion, Claire; Brodin, Priscille M; Vandeputte, Alexandre; Molendi-Coste, Olivier; Pineau, Laurent; Goormachtigh, Gautier; Pluquet, Olivier; Pourtier, Albin; Cleri, Fabrizio; Lartigau, Eric; Penel, Nicolas; Abbadie, Corinne.
Afiliación
  • Goy E; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, France.
  • Tomezak M; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, France.
  • Facchin C; Univ. Lille, CNRS, UMR8520, Institut d'Electronique, Microélectronique et Nanotechnologie, F-59652 Villeneuve d'Ascq, France.
  • Martin N; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, France.
  • Bouchaert E; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, France.
  • Benoit J; Oncovet Clinical Research, Plateforme PRECI, F-59120 Loos, France.
  • de Schutter C; Oncovet, Plateforme PRECI, F-59650 Villeneuve d'Ascq, France.
  • Nassour J; Oncovet Clinical Research, Plateforme PRECI, F-59120 Loos, France.
  • Saas L; Oncovet, Plateforme PRECI, F-59650 Villeneuve d'Ascq, France.
  • Drullion C; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, France.
  • Brodin PM; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, France.
  • Vandeputte A; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, France.
  • Molendi-Coste O; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, France.
  • Pineau L; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - CIIL - Centre d'Infection et d'Immunité de Lille, F-59000 Lille, France.
  • Goormachtigh G; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - CIIL - Centre d'Infection et d'Immunité de Lille, F-59000 Lille, France.
  • Pluquet O; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France.
  • Pourtier A; Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1011 - EGID, F-59000 Lille, France.
  • Cleri F; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, France.
  • Lartigau E; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, France.
  • Penel N; Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, France.
  • Abbadie C; Univ. Lille, CNRS, UMR8520, Institut d'Electronique, Microélectronique et Nanotechnologie, F-59652 Villeneuve d'Ascq, France.
Elife ; 112022 03 18.
Article en En | MEDLINE | ID: mdl-35302491
ABSTRACT
A rare but severe complication of curative-intent radiation therapy is the induction of second primary cancers. These cancers preferentially develop not inside the planning target volume (PTV) but around, over several centimeters, after a latency period of 1-40 years. We show here that normal human or mouse dermal fibroblasts submitted to the out-of-field dose scattering at the margin of a PTV receiving a mimicked patient's treatment do not die but enter in a long-lived senescent state resulting from the accumulation of unrepaired DNA single-strand breaks, in the almost absence of double-strand breaks. Importantly, a few of these senescent cells systematically and spontaneously escape from the cell cycle arrest after a while to generate daughter cells harboring mutations and invasive capacities. These findings highlight single-strand break-induced senescence as the mechanism of second primary cancer initiation, with clinically relevant spatiotemporal specificities. Senescence being pharmacologically targetable, they open the avenue for second primary cancer prevention.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Asunto principal: Neoplasias Primarias Secundarias / Reparación del ADN Límite: Animals Idioma: En Revista: Elife Año: 2022 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Asunto principal: Neoplasias Primarias Secundarias / Reparación del ADN Límite: Animals Idioma: En Revista: Elife Año: 2022 Tipo del documento: Article País de afiliación: Francia